{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:22:37Z","timestamp":1770960157432,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    Vincristine, a cornerstone vinca alkaloid in pediatric oncology, has historically been regarded as a low-risk agent for drug-induced acute pancreatitis (DIAP). We report the first documented pediatric case of vincristine monotherapy-associated acute pancreatitis, challenging existing toxicity paradigms. A 3.25-year-old boy with stage IV Wilms tumor developed acute-onset fever and localized periumbilical pain 48\u2005h after vincristine infusion (0.9\u2005mg), administered within standard dosing. Laboratory testing confirmed marked pancreatic hyperenzymemia (serum \u03b1-amylase 2,022\u2005U\/L, 12.5\u2009\u00d7\u2009ULN; lipase 568\u2005U\/L, 7.1\u2009\u00d7\u2009ULN), and contrast-enhanced ultrasonography revealed pancreatic edema. A Naranjo score of 7 indicated\n                    <jats:italic>probable<\/jats:italic>\n                    causality, further supported by complete symptom resolution after substitution with vindesine and no recurrence during six months of follow-up. Genetic testing showed no CEP72 (rs924607) susceptibility variant, suggesting a hypersensitivity rather than pharmacogenomic mechanism. This case highlights the need to re-evaluate vincristine's DIAP risk profile in children and supports implementing routine post-infusion monitoring of pancreatic enzymes in high-risk patients. Vindesine may serve as a safe and effective alternative agent. These findings underscore the importance of updating pediatric chemotherapy safety guidelines for vinca alkaloid-containing regimens.\n                  <\/jats:p>","DOI":"10.3389\/fped.2025.1636941","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:18:57Z","timestamp":1768205937000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Vincristine-induced acute pancreatitis in pediatric Wilms tumor: first reported case challenging previous risk classifications and proposing vigilant monitoring protocols"],"prefix":"10.3389","volume":"13","author":[{"given":"Ting","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongqiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zebin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/ijms22084112","article-title":"Vincristine-Induced peripheral neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment","volume":"22","author":"Triarico","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S0140-6736(20)31310-6","article-title":"Acute pancreatitis","volume":"396","author":"Boxhoorn","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12%3C2588::AID-CNCR24%3E3.0.CO;2-N","article-title":"Acute pancreatitis associated with continuous infusion cytarabine therapy: a case report","volume":"77","author":"McBride","year":"1996","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/00004836-198912000-00017","article-title":"Rapid development of pancreatitis following reuse of 6-mercaptopurine","volume":"11","author":"Cappell","year":"1989","journal-title":"J Clin Gastroenterol"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.22541\/au.173738716.63422238\/v1","article-title":"Pancreatitis induced by pegaspargase in children: a real-world pharmacovigilance analysis based on food and drug administration adverse event reporting system. Preprints","author":"Zhang","year":"2025"},{"key":"B6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41585-018-0100-3","article-title":"The UMBRELLA SIOP\u2013RTSG 2016 Wilms tumour pathology and molecular biology protocol","volume":"15","author":"Vujani\u0107","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e21848","DOI":"10.1097\/MD.0000000000021848","article-title":"Acute pancreatitis induced by combination chemotherapy used for the treatment of acute myeloid leukemia: a case report","author":"Yang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/humupd\/dmac039","article-title":"The impact of vincristine on testicular development and function in childhood cancer","volume":"29","author":"Clark","year":"2023","journal-title":"Hum Reprod Update"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.3390\/cancers14143510","article-title":"Genetic polymorphisms associated with vincristine pharmacokinetics and vincristine-induced peripheral neuropathy in pediatric oncology patients","volume":"14","author":"Van De Velde","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14740\/wjon1006e","article-title":"Acute pancreatitis related to a chemotherapy drug","volume":"8","author":"Murtaza","year":"2017","journal-title":"World J Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.7326\/0003-4819-97-3-453_1","article-title":"Pancreatitis and chemotherapy","volume":"97","author":"Puckett","year":"1982","journal-title":"Ann Intern Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.7326\/0003-4819-108-4-567","article-title":"Acute pancreatitis associated with chemotherapy for germ cell tumors in two patients","volume":"108","author":"Socinski","year":"1988","journal-title":"Ann Intern Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5580\/2b68","article-title":"Acute pancreatitis following VAD chemotherapy combination consisting of vincristine, doxorubicin, and dexamethasone in a newly diagnosed multiple myeloma patient: a case report","volume":"8","author":"Selami","year":"2012","journal-title":"Int J Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nrgastro.2017.13","article-title":"What\u2019s unique about acute pancreatitis in children: risk factors, diagnosis and management","volume":"14","author":"Husain","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B16","first-page":"45","article-title":"Drug-induced acute pancreatitis: a review","volume":"15","author":"Jones","year":"2015","journal-title":"Ochsner J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41575-019-0158-2","article-title":"New insights into acute pancreatitis","volume":"16","author":"Lee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.cgh.2006.11.023","article-title":"Drug-induced acute pancreatitis: an evidence-based review","volume":"5","author":"Badalov","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/BF02889240","article-title":"Cytotoxicity of vinblastine and vincristine to pancreatic acinar cells","volume":"18","author":"Nevalainen","year":"1975","journal-title":"Virchows Arch B Cell Pathol"},{"key":"B20","first-page":"103","article-title":"A pilot study evaluating changes in pancreatic lipase immunoreactivity concentrations in canines treated with L-asparaginase (ASNase), vincristine, or both for lymphoma","volume":"73","author":"Wright","year":"2009","journal-title":"Can J Vet Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13205-023-03636-6","article-title":"Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges","volume":"13","author":"Banyal","year":"2023","journal-title":"3 Biotech"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1636941\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:19:04Z","timestamp":1768205944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1636941\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":21,"alternative-id":["10.3389\/fped.2025.1636941"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1636941","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1636941"}}